Pharmacokinetics–pharmacodynamics of quinolones against Streptococcus pneumoniae in patients with community-acquired pneumonia
- 30 September 2008
- journal article
- research article
- Published by Elsevier in Diagnostic Microbiology and Infectious Disease
- Vol. 62 (1), 99-101
- https://doi.org/10.1016/j.diagmicrobio.2008.04.008
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Gemifloxacin for the Treatment of Respiratory Tract Infections: In Vitro Susceptibility, Pharmacokinetics and Pharmacodynamics, Clinical Efficacy, and SafetyPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2005
- Population Pharmacokinetics and Pharmacodynamics of Garenoxacin in Patients with Community-Acquired Respiratory Tract InfectionsAntimicrobial Agents and Chemotherapy, 2004
- Use of Pharmacodynamic End Points in the Evaluation of Gatifloxacin for the Treatment of Acute Maxillary SinusitisClinical Infectious Diseases, 2004
- Pharmacodynamics of Fluoroquinolones against Streptococcus pneumoniae in Patients with Community-Acquired Respiratory Tract InfectionsAntimicrobial Agents and Chemotherapy, 2001
- Pharmacodynamics of LevofloxacinJAMA, 1998
- Pharmacokinetics and pharmacodynamics of oral grepafloxacin in patients with acute bacterial exacerbations of chronic bronchitisJournal of Antimicrobial Chemotherapy, 1997
- Pharmacokinetics of Grepafloxacin after Oral Administration of Single and Repeat Doses in Healthy Young MalesClinical Pharmacokinetics, 1997
- Community-Acquired PneumoniaNew England Journal of Medicine, 1995
- Pharmacodynamics of intravenous ciprofloxacin in seriously ill patientsAntimicrobial Agents and Chemotherapy, 1993